Who are SSRI/Venlafaxine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Venlafaxine XR + Mirtazapine, Venlafaxine and Lamotrigine, desvenlafaxine succinate sustained release tablets, lidocaine+adjunct tramadol, SSRI/Clomipramine, desvenlafaxine SR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ssri-venlafaxine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SSRI/Venlafaxine — Competitive Intelligence Brief

SSRI/Venlafaxine (SSRI/Venlafaxine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI/Venlafaxine. Area: Psychiatry.

phase 3 SSRI/Venlafaxine Serotonin transporter, Norepinephrine transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

SSRI/Venlafaxine (SSRI/Venlafaxine) — AstraZeneca. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SSRI/Venlafaxine TARGET	SSRI/Venlafaxine	AstraZeneca	phase 3	SSRI/Venlafaxine	Serotonin transporter, Norepinephrine transporter
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
Venlafaxine and Lamotrigine	Venlafaxine and Lamotrigine	University Health Network, Toronto	marketed	SNRI + anticonvulsant combination	Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation
desvenlafaxine succinate sustained release tablets	desvenlafaxine succinate sustained release tablets	Pfizer	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter, Norepinephrine transporter
lidocaine+adjunct tramadol	lidocaine+adjunct tramadol	Bagcilar Training and Research Hospital	phase 3	Local anesthetic, weak opioid agonist	Voltage-gated sodium channels, mu-opioid receptor, serotonin transporter, norepinephrine transporter
SSRI/Clomipramine	SSRI/Clomipramine	AstraZeneca	phase 3	SSRI/SNRI	Serotonin transporter, Norepinephrine transporter
desvenlafaxine SR	desvenlafaxine SR	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter, Norepinephrine transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI/Venlafaxine class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SSRI/Venlafaxine — Competitive Intelligence Brief. https://druglandscape.com/ci/ssri-venlafaxine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab